Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness

Antiviral therapy in chronic hepatitis C (G1) in Russia: cost and effectiveness

Genotype 1 HCV treatment in Russia assume as bitherapy (pegylated interferon – PG plus ribavirin – RBV) as three therapy based on HCV protease inhibitor such as telaprevir (TLV), boceprevir (BCV) or simeprevir (SMV) plus PG/RBV. Medical technologies characterize neither clinical effectiveness, safet...

Full description

Bibliographic Details
Main Authors:	A. V. Rudakova, D. A. Gusev, A. N. Uskov, Yu. V. Lobzin
Format:	Article
Language:	Russian
Published:	Journal Infectology 2015-04-01
Series:	Журнал инфектологии
Subjects:	хронический гепатит с 1 генотип ингибиторы протеазы анализ затрат
Online Access:	https://journal.niidi.ru/jofin/article/view/381

Similar Items

Cost-effectiveness of antiviral therapy in chronic hepatitis C (G1)
by: A. V. Rudakova, et al.
Published: (2016-02-01)

COST-EFFECTIVENESS OF ANTIVIRAL THERAPY IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C (GENOTYPE 1) WITH VARIOUS SEVERITY OF FIBROSIS STAGE
by: A. V. Rudakova, et al.
Published: (2018-01-01)

Cost-effectiveness of antiviral therapy in treatment-naive patients with chronic hepatitis C (genotype 1)
by: A. V. Rudakova, et al.
Published: (2017-06-01)

Сost-effectiveness of the second wave of protease inhibitors in the treatment of chronic hepatitis C (genotype 1) in patients not previously treated with antiviral drugs, and for relapsed disease
by: A. V. Rudakova, et al.
Published: (2016-04-01)

Cost-effectiveness of narlaprevir in the chronic hepatitis C (genotype 1) therapy in treatment-naïve patients and relapsers
by: D. A. Gusev, et al.
Published: (2016-11-01)

EVALUATION OF EFFECTIVENESS OF ANTIVIRAL THERAPY FOR CHRONIC HEPATITIS C, CAUSED BY HCV GENOTYPE 6
by: D. A. Lioznov, et al.
Published: (2017-04-01)

Clinical and immunomorphological predictors of the adverse course of chronic hepatitis C
by: I. A. Karabak, et al.
Published: (2020-06-01)

CLINICAL AND MORPHOLOGICAL FEATURES OF CHRONIC HEPATITIS C IN YOUNG CHILDREN
by: S. V. Chuelov, et al.
Published: (2015-08-01)

Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis C
by: V. V. Basina, et al.
Published: (2019-12-01)

MATHEMATICAL MODELS PREDICTING LEUKOPENIA AND NEUTROPENIA IN PATIENTS WITH CHRONIC HEPATITIS C IN THE BACKGROUND INTERFERONCONTAINING SCHEMES
by: I. G. Bakulin, et al.
Published: (2016-10-01)

Фармакоэкономический анализ применения ингибиторов протеазы вируса гепатита С
Published: (2018-06-01)

THE SIGNIFICANCE OF QUANTITIES DETECTION OF СORE ANTIGEN IN BLOOD SERUM OF CHILDREN WITH HEPATITIS C
by: A. Leybman, et al.
Published: (2015-08-01)

Evaluation of Epidemiologic Peculiarities of HIV-Infection and Genotype Distribution of Hepatitis C Virus among People Living with HIV in Constituent Entities of the Far Eastern Federal District
by: E. A. Bazykina, et al.
Published: (2021-11-01)

Features of NK cell phenotype virus genotype-driven chronic viral hepatitis C
by: Andrei A. Savchenko, et al.
Published: (2023-10-01)

Efficacy and safety of сepeginterferon alfa-2b in double treatment regimen (cepeginterferon alfa-2b and ribavirin) of antiviral therapy in patients with chronic hepatitis C genotypes 2 and 3. Experience of real clinical practice
by: A. I. Pavlov, et al.
Published: (2016-11-01)

Variety of the hepatitis B virus genovariants in the military
by: Yu. V. Ostankova, et al.
Published: (2019-10-01)

PROTEASE INHIBITOR NARLAPREVIR IN THERAPY OF HEPATITIS C VIRUS GENOTYPE 1 INFECTION IN TREATMENT-NAÏVE PATIENTS WITHOUT CIRRHOSIS: PHARMACOECONOMIC EVALUATION
by: A. V. Rudakova, et al.
Published: (2017-04-01)

Iron metabolism in chronic hepatitis C patients on antiviral treatment
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Efficacy and safety of the Russian protease inhibitor narlaprevir at treatment-naive and earlier treated noncirrhotic patients with the 1st genotype chronic hepatitis C (PIONEER study)
by: M. V. Mayevskaya, et al.
Published: (2018-08-01)

Successful antiviral therapy for chronic hepatitis C in a patient after surgery for hepatocellular carcinoma (a clinical observation)
by: I. G. Nikitin, et al.
Published: (2018-08-01)

Новые стратегии лечения вирусного гепатита С при использовании ингибиторов протеазы и полимеразы
Published: (2016-12-01)

The use of sofosbuvir for the treatment of recurrent hepatitis C after liver transplantation
by: M. Sh. Khubutiya, et al.
Published: (2017-03-01)

Effectiveness of combined antyviral therapy in children with chronic hepatitis C
by: G. P. Martynova, et al.
Published: (2014-09-01)

Detection rate of specific antibodies to the HCV CORE+1 protein in “naive” cronically HCV-infected patients in depends on the stage of liver fibrosis and the HCV subtype
by: E. V. Lichnaya, et al.
Published: (2021-01-01)

Experience of combination antiviral therapy for chronic hepatitis c in HIV-infected patients in the Novgorod region
by: O V Azovtzeva, et al.
Published: (2014-12-01)

Predict of the development of lipid distress syndrome in patients with a sustained response to antiviral therapy of chronic hepatitis C
by: D. Yu. Konstantinov, et al.
Published: (2019-12-01)

The immunologic characteristic of the stages of chronic hepatitis C and an assessment of immune system factors as prognostic criteria of a current disease
by: V. Yu. Nikitin, et al.
Published: (2014-09-01)

The modern options of chronic hepatitis C antiviral therapy with daclatasvir: results of named patient program
by: V. T. Ivashkin, et al.
Published: (2018-08-01)

Leukopenia and neutropenia in chronic hepatitis C patients with various underlying combination antiviral therapy
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Рандомизированное контролируемое клинико-экономическое исследование применения Прогепара у пациентов с хроническим алкогольным гепатитом
Published: (2018-06-01)

Change of the indices of the cytokine status in patients with chronic combined hepatitis B+C in a process of antiviral therapy
by: O. L. Sobolevskaya
Published: (2014-09-01)

IMPACT OF THE ANTIVIRAL THERAPY ON CARDIAC HEMODYNAMICS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS
by: M. V. Chistyakova, et al.
Published: (2015-09-01)

Peculiarity of Clinical Course of Childhood Hepatitis C Depending on the Viral Genotype
by: E. A. Leybman, et al.
Published: (2015-02-01)

Clinical significance of anaemia in chronic hepatitis c on the combined antiviral therapy with pegylated
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Clinical significance blood platelet count in patients with chronic hepatitis C on the background of the various options combined antiviral therapy
by: K. V. Zhdanov, et al.
Published: (2014-09-01)

Antiviral therapy of chronic hepatitis C complicated by systemic cryoglobulinemic vasculitis
by: N. V. Dunaeva, et al.
Published: (2016-07-01)

Chronic viral hepatitis B and C in patients with tuberculosis: the proportion of nozoform, dynamic changes
by: S. V. Baramzina
Published: (2015-07-01)

The safety and optimal dosage of an interleukin-17A inhibitor (secukinumab) in the treatment of psoriatic arthritis in a patient with concomitant hepatitis C virus infection
by: E. E. Gubar, et al.
Published: (2019-10-01)

Influence of basal level of the general cholesterol on efficacy of antiviral therapy of the chronic hepatitis with peg-interferon-α 2B and ribavirin
by: P P Ogurtsov, et al.
Published: (2011-09-01)

Real-world effectiveness and safety of pan-genotypic antiviral therapy for chronic HCV-infection: data from three clinical centers in St. Petersburg
by: D. A. Gusev, et al.
Published: (2023-01-01)